Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/CD22 CAR-T in Pediatric MRD-Positive B-ALL
NCT06752785Phase 1Recruiting
- Start
- Oct 2024
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19/CD22 CAR-T in B cell acute lymphoblastic leukemia (B-ALL). Primary endpoint: Validity exploration at 1 year. Started Oct 2024; status: recruiting.
02
Drugs
CD19/CD22 CAR-T
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06752785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06752785.